NASDAQ : XFOR
X4 Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 3.36 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 333.13M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 332.14M |
| Enterprise Value | 201.40M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 99.15M |
| Shares Outstanding | 99.15M |
| Shares Change (YoY) | +1,374.07% |
| Shares Change (QoQ) | +0.04% |
| Owned by Insiders (%) | 0.69% |
| Owned by Institutions (%) | 62.03% |
| Float | 57.22M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 20.96 |
| Forward PS | 34.67 |
| PB Ratio | 2.07 |
| P/TBV Ratio | 2.66 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 12.71 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 11.30 |
| Quick Ratio | 10.84 |
| Debt / Equity | 0.50 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -9.23 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -113.08% |
| Return on Assets (ROA) | -28.15% |
| Return on Invested Capital (ROIC) | -326.48% |
| Return on Capital Employed (ROCE) | -34.52% |
| Weighted Average Cost of Capital (WACC) | 7.19% |
| Revenue Per Employee | $352,156 |
| Profits Per Employee | -$2.00M |
| Employee Count | 45 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 0.68 |
Taxes
| Measure | Value |
|---|
| Income Tax | -28,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.46 |
| 52-Week Price Change | -10.43% |
| 50-Day Moving Average | 3.33 |
| 200-Day Moving Average | 3.80 |
| Relative Strength Index (RSI) | 60.35 |
| Average Volume (20 Days) | 670,851 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 7.49M |
| Short Previous Month | 7.59M |
| Short % of Shares Out | 7.56% |
| Short % of Float | 13.09% |
| Short Ratio (days to cover) | 7.58 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 15.85M |
| Gross Profit | 12.92M |
| Operating Income | -80.67M |
| Pretax Income | -90.17M |
| Net Income | -90.14M |
| EBITDA | -79.00M |
| EBIT | -80.67M |
| Loss Per Share | -$0.89 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 207.97M |
| Total Debt | 77.22M |
| Net Cash | 130.75M |
| Net Cash Per Share | $1.32 |
| Equity (Book Value) | 155.45M |
| Book Value Per Share | 1.62 |
| Working Capital | 199.49M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -83.74M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 1.67M |
| Net Borrowing | n/a |
| Free Cash Flow | -83.74M |
| FCF Per Share | -$0.84 |
Margins
| Measure | Value |
|---|
| Gross Margin | 81.51% |
| Operating Margin | -509.06% |
| Pretax Margin | -568.98% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1,374.07% |
| Shareholder Yield | -1,374.07% |
| Earnings Yield | -26.47% |
| FCF Yield | -25.21% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $11.60 |
| Price Target Difference | 246.27% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 1.16% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Apr 28, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -1.99 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |